
Event Recap: RAPS Utah/BioUtah Seminar – “Transitioning to New EU MDR & EU IVDR – Post-Market Surveillance, Clinical and Usability Studies” hosted by MasterControl
April 12, 2019
Approximately 90 attendees joined us on March 28, 2019 for this event, “Transitioning to New EU MDR & EU IVDR – Post-Market Surveillance, Clinical and Usability Studies,” hosted by MasterControl.
Participants were first able to hear from the following speakers:
* Robert Wolfarth, Chapter Chair of new RAPS Utah chapter; and Senior Manager, Regulatory Affairs, Merit Medical Systems, Inc.
* Kelvyn Cullimore, President and CEO of BioUtah
* Matt Lowe, EVP of Product, MasterControl
Following the opening remarks, three life sciences professionals spoke on a general overview of the situation; Post-Market Surveillance, Vigilance and Market Surveillance; Clinical Evaluation and Clinical Investigations; and the parallel chapters of the IVDR. The speakers were Dr. Michael Rinck, PhD (managing director, pharmacist and microbiologist, Promedt Consulting GmbH), Linda Chatwin, RAC, JD (senior customer solutions consultant, Health Sciences Division, Emergo, a UL Company), and Dr. Kristen Kanack, PhD (senior vice president, regulatory and clinical affairs, BioFire Diagnostics, LLC).
The event concluded with a Q & A session between the audience and the three featured speakers.
If you missed the seminar, please still feel free to contribute to the online RAPS discussion group to continue questions: https://connect.raps.org/utah/home
Recent News
- Collaboration with Quest Diagnostics to expand kidneyintelX.dkd TM testing in the United States
- Utah Business Innovation Awards Summit Recap
- Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
- Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome


















